NCT00636740 - Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

Hormone-Refractory Prostate Cancer

Interventions

DRUG

Zoledronic Acid 20mg Tablets

Oral enteric coated tablets, 20mg, weekly, 8 weeks

DRUG

Zoledronic Acid

Zoledronic Acid infusion, 4mg, every 4 weeks for 8 weeks

DRUG

Zoledronic Acid 20mg Tablets

Oral enteric coated tablets, 20mg, once a day for 4 consecutive days during week 1, weekly for weeks 5, 6, 7, 8

Trial Locations (13)

New York Urological Associates, PC, New York

Cancer Outreach Associates, P.C., Abingdon

Charleston Hematology Oncology Associates, PA, Charleston

Cancer Care of North Florida, P.A., Lake City

Innovative Medical Research of South Florida, Inc., Miami

Lakeland Regional Cancer Center, Lakeland

Birmingham Hematology & Oncology Associates, LLC, Birmingham

Green Clinic, LLC, Ruston

East Tallinn Central Hospital, Tallinn

North Estonian Regional Hospital, Tallinn

Tartu University Hospital, Tartu

O. Hublarovs Private Practice, Daugavpils

P. Stradina Clinical University Hospital, Riga